NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,578.30 +102.38 (+0.55%) CRUDE OIL
78.89 +0.41 (+0.52%) GOLD FUTURES
2,332.70 +1.50 (+0.06%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,395.98 -639.10 (-1.25%)
Navamedic ASA (0FDB.L)
- PR Newswire
Navamedic ASA: Broad launch for Eroxon® in Sweden today
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.
- PR Newswire
Navamedic ASA: Invitation to 2024 1st quarter presentation
Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/
- PR Newswire
Navamedic welcomes new shareholders
Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1 percent interest in the company.
